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Abstract: Chemometrics-assisted spectrophotometry for the determination of two protease 
inhibitors, lopinavir and ritonavir, in plasma was evaluated. A set of calibration mixtures 
(calibration  set)  was  designed  according  to  central  composite  design.  The  UV  spectra 
obtained from the calibration set were subjected to partial least square regression (PLS-1) 
to construct the prediction models for lopinavir and ritonavir in unknown samples, which 
were  then  validated  in  a  randomly  selected  set  of  synthetic  mixtures  of  the  drugs. An 
optimum model was obtained in the wavelength ranges of 215–249 nm and 240–279 nm 
with principal components 8 for both lopinavir and ritonavir respectively. The prediction 
models were used to analyse the two drugs in plasma and the results were compared with 
those obtained by high-performance liquid chromatography (HPLC). The PLS-1 model and 
the HPLC
 method were found to be comparable. 
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INTRODUCTION  
 
Lopinavir (LPV) and ritonavir (RTV) are important HIV-1 protease inhibitors, alone or in 
combination, for highly active antiretroviral therapy (HAART) [1]. However, there is a relationship 
between protease inhibitor concentration and pharmacological activity as well as toxicity or side 
effects. In addition, wide variability in pharmacokinetics of protease inhibitors was also found [2]. To 
avoid drug toxicity and improve efficacy, therapeutic drug monitoring is required for drugs with a 
narrow therapeutic range including protease inhibitors [1, 3-5]. Several analytical methods have been  
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described for the determination of protease inhibitors and other antiretroviral agents in biological 
samples [1, 3-17]. In the past decade, a combination of antiretroviral drugs including LPV and RTV 
in human plasma was usually determined by high-performance liquid chromatography – ultraviolet 
spectroscopy  (HPLC-UV)  or  HPLC-UV/fluorescence  [3-9]. Nowadays, liquid chromatography – 
mass spectrometry (LC-MS) and LC-MS/MS are the most widely adopted methods for quantitating 
protease inhibitors including LPV and RTV in several types of samples, e.g. human plasma [10-12], 
dried blood spot [13], dried plasma spot [14] and peripheral blood mononuclear cell [1, 15-17]. 
Although LC-MS/MS seems to be the most effective instrument due to its sensitivity and specificity 
when compared with conventional HPLC-UV, the price of the instrument and professional operation 
has  been  the  limitation  on  routine  therapeutic  drug  monitoring.  On  the  other  hand,  a 
spectrophotometric  measurement  without  prior  chromatographic  separation  is  interesting  but  the 
overlap of the absorbance spectra remains problematic. However, it is possible to solve this problem 
with chemometric approaches. Among these, multivariate calibration methods such as multiple linear 
regression (MLR), principle component regression (PCR) and partial least square (PLS) utilising 
spectrophotometric data are important for the determination of drugs in combination [18-19]. In our 
previous  study  [20],  multivariate  calibration  methods,  i.e.  PCR  and  PLS-1,  were  developed  for 
determination  of  LPV  and  RTV  in  syrup.  Although  those  results  were  comparable  with  the 
developed HPLC method, the previous PCR and PLS-1 models cannot be applied to plasma samples 
owing to the difference between the syrup matrix and the human plasma matrix. A chemometrics-
assisted spectrophoto- metric method, PLS-1, is therefore developed for the determination of LPV 
and RTV in plasma samples in this study. The same sample set was also analysed by HPLC. Results 
of the two methods are then compared to determine the reliability of the chemometric approach. To 
our  knowledge,  the  determination  of  LPV  and  RTV  in  human  plasma  by  PLS-1  has  not  been 
reported.  
 
MATERIALS AND METHODS 
     
Reagents, Apparatus and Software 
 
All  standard  drugs  of  working  standard  grade  were  kindly  donated  by  the  Government 
Pharmaceutical  Organisation  (GPO),  Thailand.  Reagent-grade  hexane  and  ethyl  acetate  were 
obtained from J. T. Baker. Acetonitrile and methanol (HPLC-grade) were purchased from Labscan. 
Sodium  dihydrogen  phosphate  was  obtained  from  Merck.  The  drug-free  plasma  samples  were 
expired plasma kindly donated by Ramathibodi Hospital, Bangkok. These plasma samples were not 
in a category which needs ethics committee approval.  
UV absorbance was recorded in a 10-mm quartz cell using a PerkinElmer (Lambda 35) UV-
Visible  spectrophotometer.  Manipulation  of  the  spectral  data  was  carried  out  with  UV  Winlab 
software. The chromatographic system consisted of a Shimadzu LC-10AD, a CBM-10A (system 
controller) and a SPD-10V UV-Vis detector. Hypersil Gold C18 (250  4.6 mm i.d., particle size 5 
μm) was supplied by Thermo Scientific (USA). A 1.73-GHz Intel personal computer with Windows 
XP operating system, together with the Unscrambler
® (version 9.8) programme and other statistical 
analyses, was used to calculate the PLS model. 
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Preparation of Standard Solutions and Plasma Samples 
 
Stock solutions of LPV (1 mg L
-1) and RTV (0.5 mg L
-1) were prepared by dissolving the 
required amount of each drug in methanol. Proper dilution of each stock solution was prepared with 
50%  methanol    to  obtain  standard  solutions  for  further  use  in  the  experiments.  The  linear 
concentration range of each drug was determined by one-component calibration. The absorbance 
spectra were recorded over a range of 200–400 nm using 50% methanol as blank. 
  Each plasma sample was prepared by spiking 400 µL of drug-free blank plasma with 100 µL 
of the desired standard mixture solution. Prior to the analysis, interference from the plasma samples 
was removed by liquid-liquid extraction. The plasma samples and organic solvent were mixed and 
then centrifuged at 3000 rpm for 15 min. The organic layer was transferred to a clean tube and 
evaporated under nitrogen at 50°C in a water bath. The extract was reconstituted by adding 2 mL of 
50% methanol and centrifuged at 3000 rpm for 5 min., and 1.5 mL of the supernatant was then 
removed for analysis. For the HPLC method, the samples were cleaned and then filtered through a 
nylon membrane filter. 
   
Chemometric Method 
 
  Two  sets  of  standard  LPV-  and  RTV-spiked  plasma  samples  were  prepared.  The 
concentration of each drug in the two sets was within its respective linearity range. One set served as 
the calibration set, which consisted of 16 drug mixtures in plasma and four blank plasma samples. 
The second set was the validation set, which contained ten drug mixtures in plasma. The composition 
of the calibration set was selected based on central composite design (CCD)
 [21] while that of the 
validation set was randomly selected. Absorbance data of the two sample sets were collected at 
wavelengths  between  200-400  nm.  These  data  were  applied  to  construct  a  model  using 
Unscrambler
®  programme.  The  resulting  model  was  then  used  to  determine  the  LPV  and  RTV 
concentrations in the validation set (test set). 
 
HPLC Method 
 
  HPLC conditions, comprising acetonitrile and 25 mM phosphate buffer pH 6 (50:50 v/v) and 
a C18 column (Hypersil Gold C18, 250  4.6 mm i.d., particle size 5 μm), were developed and 
validated.  The flow rate of the system was 1 mL min
-1. The presence of the desired drugs was 
monitored  by  UV  detection  at  254  nm.  Drug-spiked  plasma  samples  were  used  for  method 
development.  To  prove  the  reliability  of  the  developed  HPLC  method,  important  validation 
parameters, i.e. linearity, accuracy, precision, specificity and system suitability, were investigated. 
Linearity was established by using the drug-mixture-spiked plasma. Six concentrations of LPV (2–20 
µg mL
-1) and RTV (0.5–8 µg mL
-1) were assessed; indinavir (IDV) at a concentration of 2 µg mL
-1 
was used as internal standard. Linearity was demonstrated by plotting the peak area ratio of the 
drugs to the internal standard versus concentration of the drugs. Regression parameters were then 
computed. For accuracy and precision, drug-free plasma was spiked with three concentrations of 
LPV (3–18 µg mL
-1) and RTV (0.75–7 µg mL
-1) with five determinations for each concentration. 
The accuracy of the developed method was expressed as per cent recovery of the amount of added 
drug vs. amount detected, while precision was expressed as the relative standard deviation (% RSD) 
of  per  cent  recovery  at  each  concentration.  The  specificity  of  the  method  was  confirmed  by 
comparing chromatograms of the drug-spiked plasma samples with those of the drug-free plasma 
samples.   
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Three parameters, namely repeatability, resolution and tailing factor, provided the basis for 
the system suitability testing. Repeatability was based on five replicates of injected-drug mixtures (10 
µg LPV mL
-1 and 3 µg RTV mL
-1). Injection repeatability was expressed as % RSD of the peak area 
ratio of the drug to internal standard obtained from five-replicate injections. The resolution (Rs) of 
each drug and its adjacent peak was calculated and the tailing factor of the peak of the desired drug 
was also investigated.       
 
RESULTS AND DISCUSSION  
  
Since the spectra of LPV and RTV strongly overlap in the wavelength region of 200–270 nm 
[20], determination of one drug in the presence of the other by univariate calibration is not possible. 
Instead, a multivariate calibration technique, i.e. partial least square regression (PLS-1), is chosen for 
this study. Due to the complexity of plasma matrix and the absence of collinearity data, the PCR is 
not chosen. 
 
PLS-1 Modelling 
 
To construct the PLS-1 model, the one-component calibration (univariate calibration) of each 
drug was initially executed. A linearity range was determined in the concentration ranges of 2–20 g 
mL
-1 and 1–6 g mL
-1 for LPV and RTV respectively. The concentrations of LPV and RTV in the 
calibration set assigned for the CCD and the randomly selected concentrations of these drugs in the 
validation set were within the linearity range (2–12 g mL
-1 for LPV and 1–4 g mL
-1 for RTV). The 
composition of the calibration set corresponding to CCD is illustrated in Table 1. Individual analytes 
were independently modelled by PLS-1 with the optimum wavelength region and number of principal 
components (PCs) or factors. The optimum wavelength region was selected by visual observation; a 
region which was less interfered by another drug was chosen for testing.  
Owing to the above-mentioned strongly overlapping drug spectra, several wavelength regions 
and PCs were studied to obtain the fitted models. Leave-one-out cross-validation (LOO-CV) was 
used to validate the PLS-1 model in the model development. The optimum number of factors (PCs) 
with  minimum  prediction  error of sum squares for an optimum model was determined from the 
model development. The optimum prediction models were achieved in the wavelength regions of 
215–249 nm with 8 PCs for LPV and 240–279 nm with 8 PCs for RTV. The resulting PLS-1 model 
for plasma samples contained more PCs than those in the PLS-1 model for syrup [20]. In plasma, the 
PCs of 8 were found to be the optimum components for both LPV and RTV models while the 
optimum PCs for LPV and RTV in syrup were 2 and 4 respectively. These may be due to a more 
complicate matrix in plasma compared to that in syrup.    
In the calibration step (model development), statistical parameters such as the root mean 
square error of calibration, the correlation coefficient (r
2) and the relative error of prediction were 
also computed. In addition, the independent set of plasma samples containing different compositions 
of LPV and RTV (test set sample) that did not contribute to the calibration step was used to evaluate 
the proposed calibration models. The statistical parameter expressing the predictive applicability of a 
regression  model  was  the  standard  error  of  prediction.  All  relevant  statistical  parameters  of  the 
optimal PLS-1 model for LPV and RTV determination were acceptable for all proposed calibration 
models as shown in Table 2. 
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                      Table 1.  Composition of calibration set corresponding to CCD  
 
Sample 
Concentration (μg mL
-1)  Coded level [22] 
LPV  RTV  LPV  RTV 
1  0  2.0  - α  0 
2  16.0  2.0  + α  0 
3  8.0  0  0  - α 
4  8.0  4.0  0  + α 
5  2.3  0.6  - 1  - 1 
6  2.3  3.4  - 1  + 1 
7  13.7  3.4  + 1  + 1 
8  13.7  0.6  + 1  - 1 
9  8.0  2.0  0  0 
10  8.0  2.0  0  0 
11  8.0  2.0  0  0 
12  8.0  2.0  0  0 
13  8.0  2.0  0  0 
14  8.0  2.0  0  0 
15  8.0  2.0  0  0 
16  8.0  2.0  0  0 
    
 
     Table 2.  Statistical parameters of the optimum PLS-1 model for LPV and RTV determination 
 
Parameter  LPV  RTV 
Spectral range (nm)  215 – 249  240 – 279 
PCs  8  8 
PRESS  0.6371  0.0213 
RMSEC  0.1675  0.0365 
r
2  0.9976  0.9986 
REP (%)  2.50  1.82 
SEP  0.3706  0.2144 
SEN  1.02 × 10
-3  7.96 × 10
-4 
SEL  9.60 × 10
-3  6.16 × 10
-3 
 
Note:  PRESS = prediction error of sum squares; PCs = number of principle component; RMSEC = root 
mean square error of calibration; r
2 = correlation coefficient; REP = relative error of the prediction; SEP = 
standard error of prediction; SEN = sensitivity; SEL = selectivity. 
 
    The proposed models were also validated in terms of linearity, accuracy, precision and limit 
of quantitation in order to show that the chemometric method is appropriate to the investigation of 
LPV and RTV in plasma samples by spiking plasma with different concentrations of the two drugs. 
Table  3  shows  that  all  parameters  meet  the  requirements  of  the  bioanalytical method  validation 
guidelines [23]. 
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                          Table 3.  Results of validation of PLS-1 model for LPV and RTV 
 
Parameter
a  LPV  RTV 
Spectral range (nm)  215 – 249  240 – 279 
PCs  8  8 
Linearity  0.9988  0.9975 
Accuracy  104  96 
Repeatability  5.07  5.85 
Inter-day precision  5.00  4.73 
LOQ  1.77  0.51 
 
a Linearity is expressed as the correlation coefficient (r
2) and accuracy as the average % recovery (n=15). 
Precision is expressed as relative standard deviation (% RSD) and consists of repeatability (n=15) and inter-
day precision (n = 5). Limit of quantitation (LOQ) was calculated by the formula: LOQ = 10(SD/S), where 
SD is the standard deviation of the response and S is the slope of calibration curve. 
 
HPLC Method Development and Method Validation 
 
  LPV and RTV can be well separated from each other and from other interferences present in 
plasma. The retention times of LPV, RTV and the internal standard IDV are 12.23 min., 10.55 min. 
and 5.16 min. respectively. Both LPV and RTV exhibit a linear relationship in a graph of the peak 
area ratio vs. concentration over the entire concentration range (2–20 µg mL
-1 for LPV and 0.5–8 µg 
mL
-1 for RTV) with acceptable linear regression parameters (Table 4). The stability of the proposed 
method was evaluated by studying the variation in the peak area ratio of LPV and RTV in drugs-
spiked plasma.  
 
      Table 4.  Summary of validation results and system suitability parameters for HPLC method   
 
Parameter (Unit)  LPV  RTV 
Linearity range (µg mL
-1)  2-20  0.5-8 
r
2  0.9917  0.9983 
Slope   0.0913   0.7261  
Intercept   0.0183   0.1118  
Repeatability (% RSD, n=5)  1.43-2.62  0.73-3.37 
Intermediate precision (% RSD, n=5)  2.10-3.89  2.03-7.86 
Recovery (%)  100-104  86-101 
Repeatability of peak area ratio (% RSD, n=5)  1.92  0.57 
Limit of quantitation (µg mL
-1)  2.96  0.96 
Resolution  4.91  5.18 
Tailing factor  1.08  1.09 
 
As  summarised  in  Table  4,  the  repeatability  (intra-day  precision)  of  the  determination is 
indicated by the % RSD value for plasma analyses, which range between 1.43–2.62% for LPV and 
0.73–3.37% for RTV. The intermediate precision (inter-day precision) RSD values obtained for the 
drugs-spiked  plasma  samples  are  below  3.89%  for  LPV  and  7.86%  for  RTV  over  the  entire 
concentration range of 3–18 µg mL
-1 for LPV and 0.75–7 µg mL
-1 for RTV. The results show that  
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the precision of the proposed HPLC method is satisfactory for the analysis of LPV and RTV in 
plasma samples. The accuracy of the method is expressed as per cent recovery of the added drug. 
The mean recoveries are 100–105% for LPV over the concentration range of 3–18 µg mL
-1 and 86–
101% for RTV over the concentration range of 0.75–7 µg mL
-1. All figures of merit for method 
validation meet the requirements of the bioanalytical guidelines [23].  
The specificity of the method is illustrated in Figure 1. A comparison of the chromatogram of 
the drug-spiked plasma and that of the drug-free plasma shows that the endogenous substances in 
plasma do not elute at the retention times of LPV and RTV, indicating that LPV and RTV can be 
separated from the sources of interference present in plasma. Additionally, the precision of retention 
time, resolution and tailing factor (asymmetric peak), the three criteria used to assess the system 
suitability of the HPLC conditions, are all acceptable (Table 4).  
 
 
 
Figure 1.  (A) Chromatogram of LPV (10 µg mL
-1), RTV (3 µg mL
-1) and IDV (2 µg mL
-1) spiked 
in plasma; (B) Chromatogram of drug-free plasma sample with expected retention times of IDV, 
RTV and LTV  
 
 
 
 
min. 
min.  
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Comparison of Chemometric and HPLC Methods   
 A set of 10 mixture samples, apart from those used in calibration step, were prepared and 
analysed using the developed HPLC method and PLS-1 model. The mean recoveries of LPV and 
RTV  from  human  plasma  obtained  from  the  two  methods  were  then  compared  by  using  t-test 
statistic. As shown in Table 5, the mean recovery results for the LPV- and RTV-spiked in plasma are 
not significantly different at the 95% confidence limit. These results indicate that the simple and rapid 
chemometric method can be used as an alternative to the HPLC method for the determination of 
LPV and RTV in plasma.  
 
Table 5.  Mean recoveries of LPV and RTV obtained using PLS-1 optimum model compared with 
HPLC method    
 
LPV  RTV 
Parameter  HPLC  PLS-1  Parameter   HPLC  PLS-1 
Mean % recovery 
(n=10) 
106  103 
Mean % recovery 
(n=10) 
96  98 
% RSD  3.37  4.29  % RSD  3.15  6.63 
 
CONCLUSIONS   
 
The developed PLS-1 model, employing UV absorbance data successfully determined LPV 
and RTV concentrations in plasma. Validation of the reliability of the PLS-1 prediction model gave 
acceptable validation results and was not significantly different from the reference HPLC method in 
the  determination  of  LPV  and  RTV,  which  shows  that  this  chemometrics-assisted  spectro-
photometric  method  can  be  used  as  an  alternative  to  HPLC  in  the  determination  of  the  drug 
mixtures.   
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